Pure Global
NCT06289361

Cohort IMEA 070 -Lenacapavir Compassional

Immunovirological Follow-up and Safety of HIV-infected Patients Receiving Lenacapavir Under Compassionate Access in France Between 01/01/2021 and 12/31/2023
Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba·ClinicalTrials.govNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
HIV Infections
Study type
Observational
Sponsor & location
Primary sponsor
Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba
Location
Fort-de-France,Bobigny,Bordeaux,Bordeaux,Garches,La Roche Sur Yon,Le Chesnay,Lorient,Nice,Paris,Paris,Paris,Paris,Paris,Saint-Denis,Suresnes, France
Timeline & enrollment
Phase
N/A
Start date
Apr 01, 2024
End date
Jul 30, 2024
Enrollment
58 participants
Primary outcome

proportion of participants with plasma HIV RNA 50 copies/ml 26 weeks after first LEN injection

Summary

Immunovirological follow-up and safety of HIV-infected patients receiving lenacapavir under
 compassionate access in France between 01/01/2021 and 12/31/2023

ICD-10 classifications
HIV disease resulting in other viral infectionsHIV disease resulting in other bacterial infectionsHIV disease resulting in multiple infectionsAcute HIV infection syndromeHIV disease resulting in other infectious and parasitic diseases
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06289361
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06289361 through Pure Global AI's free database. This phase not specified trial is sponsored by Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba and is currently Not yet recruiting. The study focuses on HIV Infections. Target enrollment is 58 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.